Literature DB >> 30879124

Re: A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills? From Slaoui et al., World J urol 2019. Long-term safety of local radiation therapy of newly diagnosed low burden metastatic prostate cancer: an unaddressed concern.

Bernardo Rocco1, Sighinolfi Maria Chiara2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30879124     DOI： 10.1007/s00345-019-02714-w

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  6 in total

1.  Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial.

Authors:  Prasanna Sooriakumaran
Journal:  BJU Int       Date:  2017-07-16       Impact factor: 5.588

2.  Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.

Authors:  Axel Heidenreich; David Pfister; Daniel Porres
Journal:  J Urol       Date:  2014-09-22       Impact factor: 7.450

3.  Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.

Authors:  Raj Satkunasivam; Andre E Kim; Mihir Desai; Mike M Nguyen; David I Quinn; Leslie Ballas; Juan Pablo Lewinger; Mariana C Stern; Ann S Hamilton; Monish Aron; Inderbir S Gill
Journal:  J Urol       Date:  2015-02-21       Impact factor: 7.450

4.  A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

Authors:  Amine Slaoui; S Albisinni; F Aoun; G Assenmacher; W Al Hajj Obeid; R Diamand; S Regragui; A Touzani; A Bakar; A Mesfioui; T Karmouni; A Ameur; K Elkhader; A Koutani; A Ibnattya; T Roumeguere; A Peltier
Journal:  World J Urol       Date:  2019-01-31       Impact factor: 4.226

Review 5.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Authors:  Claire L Vale; Sarah Burdett; Larysa H M Rydzewska; Laurence Albiges; Noel W Clarke; David Fisher; Karim Fizazi; Gwenaelle Gravis; Nicholas D James; Malcolm D Mason; Mahesh K B Parmar; Christopher J Sweeney; Matthew R Sydes; Bertrand Tombal; Jayne F Tierney
Journal:  Lancet Oncol       Date:  2015-12-21       Impact factor: 41.316

6.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Authors:  Christopher C Parker; Nicholas D James; Christopher D Brawley; Noel W Clarke; Alex P Hoyle; Adnan Ali; Alastair W S Ritchie; Gerhardt Attard; Simon Chowdhury; William Cross; David P Dearnaley; Silke Gillessen; Clare Gilson; Robert J Jones; Ruth E Langley; Zafar I Malik; Malcolm D Mason; David Matheson; Robin Millman; J Martin Russell; George N Thalmann; Claire L Amos; Roberto Alonzi; Amit Bahl; Alison Birtle; Omar Din; Hassan Douis; Chinnamani Eswar; Joanna Gale; Melissa R Gannon; Sai Jonnada; Sara Khaksar; Jason F Lester; Joe M O'Sullivan; Omi A Parikh; Ian D Pedley; Delia M Pudney; Denise J Sheehan; Narayanan Nair Srihari; Anna T H Tran; Mahesh K B Parmar; Matthew R Sydes
Journal:  Lancet       Date:  2018-10-21       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.